Skip to content
Search

Latest Stories

Pfizer to axe 500 jobs as part of its cost-cutting campaign

The US drugmaker eliminated 100 jobs at one of its manufacturing plants in Ireland last week

Pharma giant, Pfizer has announced plans to cut 500 jobs at its Sandwich site in Kent, England as part of its ongoing $3.5 billion cost-cutting drive.


The company is also planning to shut its Pharmaceutical Sciences Small Molecule (PSSM) capabilities at the site, a spokesperson of the company told FiercePharma.

However, the Sandwich site will remain open and other functions will continue with “a different size," the spokesperson added.

Currently, around 940 people are employed at the site, which is the location where Pfizer scientists first discovered Viagra.

“We are proud of our heritage of breakthrough science in the UK and we will retain a scientific presence in the U.K. including at our Discovery Park location in Sandwich,” Pfizer’s spokesperson confirmed in an email to FiercePharma.

The US drugmaker announced a global “cost realignment program” in mid-October after sales of its COVID-19 Comirnaty and antiviral Paxlovid dropped rapidly.

Layoffs have happened across Pfizer ever since the company unveiled its campaign to reduce $3.5 billion in annual costs by the end of 2024.

Last week, Pfizer eliminated 100 jobs at one of its Irish manufacturing plants in Newbridge in Kildare.

Those workers were engaged in the production of its oral COVID med Paxlovid, the company confirmed at the time.

Prior to that, Pfizer had announced that it would cut roughly 200 positions at its Kalamazoo site in Michigan.

The drug maker has also confirmed plans to close its Peapack facility in New Jersey in early 2024.

"Various areas of Pfizer's global enterprise are making changes to operate more efficiently and effectively. These changes will be implemented on a rolling basis and will differ from area to area," the company spokesperson told Reuters.

The company informed the publication that it would be sharing further details on the program as part of the full-year forecast for 2024.

An earlier report by local news outlet Kent Online stated that Pfizer was planning to discontinue all lab and manufacturing work at the Sandwich site.

The move was unexpected as the company had invested 10 million pounds sterling in advanced manufacturing technology to accelerate the development of COVID-19 drugs at the plant, Kent Online reported.

Pfizer, however, did not disclose when the layoffs at the Sandwich site will go into effect.

Meanwhile, more layoffs are expected in the coming weeks and months as Pfizer, which employs roughly 83,000 people globally, continues its cost-reduction program.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less